Skip to Main Content

Are law-breaking pharma executives the new mob bosses? Can genome editing prevent heart attacks? And can the FDA regulate drug prices?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Ed Silverman joins us to discuss how the recent convictions of executives at Insys Therapeutics could shape the way drug companies are held accountable for misdeeds. Then, we break down a curious drug approval that will break up a rare disease monopoly. Finally, STAT’s Sharon Begley stops by to explain an audacious startup’s plan to take CRISPR from niche uses to the medical mainstream.

For more on what we cover, here’s Ed on Insys; here’s the story of the FDA approval; and here’s more on the CRISPR cardiology startup.


We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].